Target Information

Target General Infomation
Target ID
T67079
Former ID
TTDC00186
Target Name
Interleukin-9
Gene Name
IL9
Synonyms
IL-9; P40 cytokine; T-cell growth factor P40; IL9
Target Type
Clinical Trial
Disease Asthma [ICD10: J45]
Function
Supports IL-2 independent and IL-4 independent growth of helperT-cells.
BioChemical Class
Cytokine: interleukin
Target Validation
T67079
UniProt ID
P15248
Sequence
MLLAMVLTSALLLCSVAGQGCPTLAGILDINFLINKMQEDPASKCHCSANVTSCLCLGIP
SDNCTRPCFSERLSQMTNTTMQTRYPLIFSRVKKSVEVLKNNKCPYFSCEQPCNQTTAGN
ALTFLKSLLEIFQKEKMRGMRGKI
Drugs and Mode of Action
Drug(s) MEDI-528 Drug Info Phase 2 Asthma [522773], [889340], [889344], [889345], [889351]
Inhibitor MEDI-528 Drug Info [550288]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
KEGG Pathway Cytokine-cytokine receptor interaction
Jak-STAT signaling pathway
Asthma
NetPath Pathway TCR Signaling Pathway
IL2 Signaling Pathway
PANTHER Pathway Interleukin signaling pathway
WikiPathways TCR Signaling Pathway
IL-9 Signaling Pathway
References
Ref 522773ClinicalTrials.gov (NCT00968669) A Study to Evaluate the Effectiveness and Safety of MEDI-528 in Adults. U.S. National Institutes of Health.
Ref 889340ClinicalTrials.gov (NCT00394654) A Study to Evaluate the Efficacy of MEDI-528 on Late Asthmatic Response With Atopic Asthma
Ref 889344ClinicalTrials.gov (NCT00483041) A Study to Evaluate the Effect of a Single-Dose Intravenous Administration of MEDI-528
Ref 889345ClinicalTrials.gov (NCT00507130) A Study to Evaluate the Safety and Tolerability of the Administration of MEDI-528 When Administered in Multiple Doses to Adults With Mild Persistent Asthma
Ref 889351ClinicalTrials.gov (NCT00590720) A Phase 2A Study to Evaluate the Safety and Effect on Exercise Challenge Testing of MEDI-528 in Adults With Asthma
Ref 550288Clinical pipeline report, company report or official report of AstraZeneca (2009).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.